Mersana Therapeutics, Inc (MRSN)

Etorro trading 970x250
Mersana Therapeutics, Inc (MRSN) Logo

About Mersana Therapeutics, Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139

Mersana Therapeutics, Inc News and around…

Latest news about Mersana Therapeutics, Inc (MRSN) common stock and company :

Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership
25 Oct, 2021 Yahoo! Finance

Brian DeSchuytner named SVP and Chief Financial OfficerCAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume

Mersana Therapeutics Enters Oversold Territory (MRSN)
22 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)
19 Oct, 2021 FinancialContent
Hedge Funds Are Betting On Mersana Therapeutics, Inc. (MRSN)
18 Oct, 2021 Yahoo! Finance

In this article we will analyze whether Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)
12 Oct, 2021 FinancialContent
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
08 Oct, 2021 FinancialContent

Mersana Therapeutics Inc(NASDAQ: MRSN) hasannounced new preclinical dataof XMT-2056. Data were presented at the ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 Oct, 2021 Yahoo! Finance

Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarksXMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing for broad combinability with approved and investigational

Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)
05 Oct, 2021 FinancialContent
The Math Shows IBB Can Go To $199
04 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Biotechnology ETF (IBB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $199.35 per unit.

First Week of May 2022 Options Trading For Mersana Therapeutics (MRSN)
01 Oct, 2021 FinancialContent

Investors in Mersana Therapeutics Inc (MRSN) saw new options become available this week, for the May 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent
72 Biggest Movers From Yesterday
14 Sep, 2021 FinancialContent

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from ...

Is Mersana Stock a Buy Right Now? This Is What You Need to Know
13 Sep, 2021 Yahoo! Finance

If you’re after big returns, the biotech sector is your go-to destination, although investors should proceed with caution as instead of mighty gains a portfolio can also dwindle alarmingly if a company in the highly volatile sector fails to deliver the goods. Which is what investors evidently felt after taking in the latest news out of Mersana Therapeutics (MRSN) HQ. On Friday, shares shed about 40% of their value after the company provided a clinical trial update. The company disclosed interim

Noteworthy Monday Option Activity: CVNA, MRSN, DEN
13 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Carvana Co (CVNA), where a total of 7,678 contracts have traded so far, representing approximately 767,800 underlying shares. That amounts to about 102.3% of CVNA's average daily trading volume over the past month of 750,875 shares..

45 Stocks Moving In Monday's Mid-Day Session
13 Sep, 2021 FinancialContent

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news ...

60 Biggest Movers From Friday
13 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

12 Health Care Stocks Moving In Friday's Intraday Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC ...

41 Stocks Moving In Friday's Mid-Day Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its ...

Why Are Mersana Therapeutics Shares Trading Lower On Friday?
10 Sep, 2021 FinancialContent

Mersana Therapeutics Inc(NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to ...

Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
10 Sep, 2021 FinancialContent

Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also ...

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Mersana Therapeutics to Present at Upcoming Investor Conferences
07 Sep, 2021 FinancialContent
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
05 Sep, 2021 FinancialContent

Biotech stocks extended their gains in the week endingSept. 3, partly aided by the broader market strength. The news flow was ...

Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study
01 Sep, 2021 FinancialContent

Conference call and webcast on Friday, September 10, 2021, at 8:00 a.m. ET featuring lead investigator Debra L. Richardson, MD

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Aug, 2021 FinancialContent
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer
16 Aug, 2021 FinancialContent

Dr. Misra to succeed Michael Kaufman, Ph.D., Chief Manufacturing Officer, who will retire in September 2021 following a planned transition period

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
06 Aug, 2021 FinancialContent
Earnings Scheduled For August 6, 2021
06 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at ...

Mersana Therapeutics, Inc (MRSN) is a NASDAQ Common Stock listed in , ,

970x250